DDInter416 DDInter1678
This drug is a broad spectrum antimycotic or antifungal agent. Clotrimazole's antimycotic properties were discovered in the late 1960s. Clotrimazole falls under the _imidazole_ category of _azole_ antifungals, possessing broad-spectrum antimycotic activity. It is available in various preparations, including creams, pessaries, and troche formulations (slowly dissolving tablets). As well as its antifungal activity, clotrimazole has become a drug of interest in treating several other diseases such as sickle cell disease, malaria and some cancers. The minimal side effect profile of this drug and its uncomplicated metabolic profile have led it to gain widespread acceptance for the treatment of mycotic outbreaks such as vaginal yeast infections as well as athlete's foot.
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants. In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa). Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis. The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with tuberous sclerosis complex.
Clotrimazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Sirolimus
Clotrimazole {u} (Compound) upregulates {v} (Gene) PCK2
PCK2 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Clotrimazole {u} (Compound) upregulates {v} (Gene) PHGDH
PHGDH {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Clotrimazole {u} (Compound) causes {v} (Side Effect) Aspartate aminotransferase increased
Aspartate aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Sirolimus
Clotrimazole {u} (Compound) resembles {v} (Compound) Sulfinpyrazone
Sulfinpyrazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Clotrimazole {u} (Compound) resembles {v} (Compound) Methadone
Methadone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Clotrimazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Tacrolimus
Tacrolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Clotrimazole {u} (Compound) upregulates {v} (Gene) PCK2
PCK2 {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Clotrimazole {u} (Compound) upregulates {v} (Gene) PHGDH
PHGDH {u} (Gene) is regulated by {v} (Gene) MTOR
MTOR {u} (Gene) is bound by {v} (Compound) Sirolimus
Clotrimazole {u} (Compound) causes {v} (Side Effect) Aspartate aminotransferase increased
Aspartate aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Clotrimazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)
Clotrimazole (Compound) upregulates PCK2 (Gene) and PCK2 (Gene) is upregulated by Sirolimus (Compound)
Clotrimazole (Compound) upregulates PHGDH (Gene) and PHGDH (Gene) is downregulated by Sirolimus (Compound)
Clotrimazole (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Sirolimus (Compound)
Clotrimazole (Compound) resembles Sulfinpyrazone (Compound) and Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Clotrimazole (Compound) resembles Methadone (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Clotrimazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Tacrolimus (Compound) and Tacrolimus (Compound) resembles Sirolimus (Compound)
Clotrimazole (Compound) upregulates PCK2 (Gene) and PCK2 (Gene) is upregulated by Temsirolimus (Compound) and Temsirolimus (Compound) resembles Sirolimus (Compound)
Clotrimazole (Compound) upregulates PHGDH (Gene) and PHGDH (Gene) is regulated by MTOR (Gene) and MTOR (Gene) is bound by Sirolimus (Compound)
Clotrimazole (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Temsirolimus (Compound) and Temsirolimus (Compound) resembles Sirolimus (Compound)